Table: Incidence rates of NTM isolated from the respiratory tract of ICU patients.

| NTM                          | Outbreak cases/10,000 patient-days | Intervention cases/10,000 patient-days | IRR (95% CI) | P-value |
|------------------------------|-----------------------------------|----------------------------------------|-------------|---------|
| M. abscessus                 | 16.6                              | 2.3                                    | 0.14 (0.07–0.27) | <0.0001 |
| M. chelonae/immunogenenum    | 12.0                              | 1.7                                    | 0.14 (0.06–0.30) | <0.0001 |
| M. avium complex             | 7.4                               | 3.6                                    | 0.48 (0.24–0.94) | 0.03    |
| M. gordoniae                 | 4.6                               | 0.8                                    | 0.18 (0.06–0.57) | 0.001   |
| Other NTM                    | 0.5                               | 1.7                                    | 3.58 (0.46–29.62) | 0.20    |
| All NTM (Total)              | 41.0                              | 9.9                                    | 0.24 (0.17–0.34) | <0.0001 |

Disclosures. All authors: No reported disclosures.

928. Major Decrease in Prevalence of Hepatitis C Viremia in Key Populations following the Second Year of Treatment as Prevention for Hepatitis C (TraP HepC) Program in Iceland
Magnus Gottfredsson, MD, PhD1; Thorarin Tyringsson, MD, MD2; Valgerdur Runarsdottir, MD, MD2; Ingunn Hansdottir, PhD2; Ottar M. Bergmann, MD1; Einar S. Bjornsson, MD, PhD2; Birger Johannsson, MD1; Bryndis Sigurdardottir, MD2; Ragnheidur H. Fridriksdottir, RN, MSc1; Arthur Love, MD, PhD1; Thorvardur J. Love, MD, PhD1; Gudrun Sigmundsdottir, MD, PhD1; Ubaldo Hernandez, MSc2; Maria Heimsdottir, MD, PhD, MBA1 and Sigurdur Olafsson, MD2; 1Infectious Diseases, Landspitali University Hospital, Reykjavik, Iceland; 2Vogur Hospital, Reykjavik, Iceland; 3Gastroenterology and Hepatology, Landspitali University Hospital, Reykjavik, Iceland; 4Virology, Landspitali University Hospital, Reykjavik, Iceland; 5Science, Landspitali University Hospital, Reykjavik, Iceland; 6State Epidemiologist, Directorate of Health, Reykjavik, Iceland and 7Finance, Landspitali University Hospital, Reykjavik, Iceland

Session: 114. Hepatitis C: Epidemiology and Elimination
Friday, October 5, 2018: 8:45 AM

Background. Hepatitis C Virus (HCV) commonly affects people who inject drugs (PWID) and/or with history of injection drug use (IDU). They are also disproportionately represented in addiction treatment centers and the penitentiary system. In order to curtail spread of HCV it is therefore important to approach these groups. PWID and prisoners have been prioritized in the TraP HepC program. The impact can thus be assessed by monitoring HCV prevalence at sentinel sites, such as addiction hospitals and prisons.

Methods. TraP HepC offers direct-acting antiviral agents (DAAs) to all HCV patients in Iceland, starting in January 2016. HCV PCR is performed at the end of treatment and 12 weeks later (SVR12). PWID and prisoners are monitored for reinfection and retreated if needed. We compared the prevalence of HCV viremia among PWID admitted for treatment at Vogur addiction hospital and inmates of the penitentiary system, before and after 2 years of TraP HepC.

Results. Two years into the program 667 patients had been evaluated of which 632 were initiated on their first course of DAAs and 7 were pending, representing 80% of the estimated total patient population. Of those who completed first treatment according to guidelines the SVR12 is 95.5%. Drop-out from first treatment was 8.2%; nevertheless, the prevalence of viremia among patients with history of IDU but not recently injecting fell from 27.4% (2012–2015) to 19.8% in 2016 and 4.1% in 2017 (P < 0.001). Likewise, the prevalence of viremia among inmates of the penitentiary system was 29% prior to initiation of TraP HepC, dropping to 7% in 2017 (P < 0.01). These results are not explained by declining IDU in the community.

Conclusion. On a population level the domestic transmission of HCV can be reduced by DAAs when combined with other efforts. Two years into the TraP HepC program the prevalence of viremia among two of the most important drivers of the epidemic has been markedly reduced. The program is ongoing, with further emphasis on increased intensity of screening, retreatment and harm reduction.

Disclosures. All authors: No reported disclosures.

930. HCV Treatment Is Associated With a Reduced Risk of Cardiovascular Disease Events: Results From ERCHIVES
Adeel Ajwad Butt, Professor of Medicine/Professor of Healthcare Policy and Research1; Peng Yan, MD2; Ashfaq Shuaib, MD3; Abdul-Badi Abou-Samra, MD, PhD4; Obaid Saikh, MD2 and Matthew Freberg, MD, MSc2; 1Medicine, Weill Cornell Medical College, New York, New York; 2VA Pittsburgh Healthcare System, Pittsburgh, Pennsylvania, 3University of Alberta, Alberta, Alberta, Canada, 4Hamad Medical Corporation, Doha, Qatar; 5Division of Cardiovascular Medicine, Vanderbilt University, Nashville, Tennessee

Session: 114. Hepatitis C: Epidemiology and Elimination
Friday, October 5, 2018: 8:45 AM

Background. Studies reporting on the association between HCV and cardiovascular disease (CVD), and effect of HCV treatment upon future risk of CVD have shown mixed results.

Methods. Within ERCHIVES (Electronically Retrieved Cohort of HCV Infected Veterans), we identified all persons treated for ≥27 weeks and propensity-score-matched group who never received HCV treatment. We excluded those with HIV, HBV, or previously diagnosed CVD. Incidence rate (per 1,000 person-years) and risk factors for CVD events (Cox proportional hazards analysis) were determined for various treatment groups. CVD events were identified using ICD-9CM/ICD-10 codes. Kaplan–Meier plots were generated to show and compare CVD-free survival by treatment status and attainment of SVR.

This abstract has been withdrawn at the author's request.